제제 개발 아웃소싱 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 제제별, 치료 영역별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Formulation Development Outsourcing Market Summary

The global formulation development outsourcing market size was valued at USD 40.1 billion in 2025 and is projected to grow from USD 43.3 billion in 2026 to USD 79.8 billion by 2033, at a CAGR of 9.1% from 2026 to 2033. Asia Pacific dominated the market, accounting for the largest revenue share of 45.7% in 2025. The formulation development outsourcing industry is experiencing growth due to an expanding pharmaceutical and biotechnology pipeline, increasing complexity of drug formulations, rising demand for specialized drug delivery technologies, and the growing outsourcing of research and development activities to contract service providers.

Pharmaceutical and biotechnology companies are increasingly relying on contract development organizations (CDOs), contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs) to access specialized scientific expertise, advanced formulation technologies, and regulatory support while reducing development timelines and optimizing operational costs. The growing prevalence of poorly soluble molecules, biologics, peptides, and complex drug products has further accelerated demand for outsourced formulation development services.

The increasing number of drug candidates entering preclinical and clinical development remains a primary growth driver for the market. Modern drug candidates frequently require advanced formulation approaches to improve solubility, bioavailability, stability, and patient compliance. This has increased demand for specialized services, including preformulation studies, formulation optimization, analytical method development, stability testing, scale-up, and technology transfer. As a result, leading service providers continue to expand their formulation development capabilities and invest in advanced drug delivery platforms. For instance, in February 2025, Recipharm AB opened a new Pilot Scale Development Centre in Germany, expanding its product development capabilities for oral solid dosage forms. The facility enhances GMP pilot-scale development, technology transfer, and small-scale manufacturing while complementing the company's existing capabilities in oral solids, sterile fill & finish, and biologics. Such investments strengthen end-to-end development capabilities and address increasing outsourcing demand from pharmaceutical and biotechnology companies.

Global Formulation Development Outsourcing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global formulation development outsourcing market report based on service, formulation, therapeutic area, end-use, and region:

• Service Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Preformulation
• Formulation Development
• Formulation Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oral
• Injectable
• Topical
• Others
• Therapeutic Area Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oncology
• Infectious Disease
• Neurology
• Hematology
• Respiratory
• Cardiovascular
• Dermatology
• Others
• End-use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pharmaceutical and Biopharmaceutical Companies
• Government and Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Formulation
  • 1.2.3. Therapeutic Area
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Formulation Development Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Clinical Trials Volume Analysis (2025)
  • 3.3.1. Total Number of Clinical Trials By Region
  • 3.3.2. Total Number of Clinical Trials, By Phase
  • 3.3.3. Total Number of Clinical Trials, By Study Design
  • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
• 3.4. Technology Landscape
• 3.5. Pricing Model Analysis
• 3.6. Tariff Impact Analysis
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Formulation Development Outsourcing Market: Service Estimates & Trend Analysis

• 4.1. Formulation Development Outsourcing Market, By Service: Segment Dashboard
• 4.2. Formulation Development Outsourcing Market, By Service: Movement Analysis
• 4.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033
• 4.4. Preformulation
  • 4.4.1. Preformulation Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.5. Formulation Development
  • 4.5.1. Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Formulation Development Outsourcing Market: Formulation Estimates & Trend Analysis

• 5.1. Formulation Development Outsourcing Market, By Formulation: Segment Dashboard
• 5.2. Formulation Development Outsourcing Market, By Formulation: Movement Analysis
• 5.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Formulation, 2021 - 2033
• 5.4. Oral
  • 5.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.5. Injectable
  • 5.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.6. Topical
  • 5.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Formulation Development Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Formulation Development Outsourcing Market, By Therapeutic Area: Segment Dashboard
• 6.2. Formulation Development Outsourcing Market, By Therapeutic Area: Movement Analysis
• 6.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.5. Infectious Disease
  • 6.5.1. Infectious Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.6. Neurology
  • 6.6.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.7. Hematology
  • 6.7.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.8. Respiratory
  • 6.8.1. Respiratory Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.9. Cardiovascular
  • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.10. Dermatology
  • 6.10.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.11. Others
  • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Formulation Development Outsourcing Market: End Use Estimates & Trend Analysis

• 7.1. Formulation Development Outsourcing Market, By End Use: Segment Dashboard
• 7.2. Formulation Development Outsourcing Market, By End Use: Movement Analysis
• 7.3. Formulation Development Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033
• 7.4. Pharmaceutical and Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.5. Government and Academic Institutes
  • 7.5.1. Government and Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 8. Formulation Development Outsourcing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. SGS S.A.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Intertek Group plc
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Recipharm
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Lonza
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Charles River Laboratories
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Eurofins Scientific SE
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Element
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Labcorp
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Thermo Fisher Scientific, Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Catalent Inc.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives